Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
KVUE•A U.S. appeals court rejected Kenvue’s request to reconsider a ruling reviving about 500 lawsuits alleging Tylenol use during pregnancy is linked to autism and ADHD. Kenvue said it plans to appeal to the U.S. Supreme Court.
1. Court rejects rehearing
The 2nd U.S. Circuit Court of Appeals in Manhattan rejected Kenvue’s request to reconsider a three-judge panel’s ruling or have the full court hear the case. The ruling revived about 500 lawsuits filed by parents alleging Tylenol use during pregnancy is linked to autism and attention deficit hyperactivity disorder in children.
2. Expert testimony dispute
The appeals court ruled in July that a district judge improperly excluded testimony from three doctors supporting the parents’ claims. Kenvue had argued that district judges are the “true gatekeepers” for deciding whether evidence is reliable enough to be admitted at trial.
3. Kenvue plans appeal
A Kenvue spokesperson said the company plans to appeal to the U.S. Supreme Court, saying the 2nd Circuit ignored federal judiciary safeguards for evaluating expert testimony. The spokesperson said the company stands by its product’s safety. The article says there is no firm scientific evidence of a link between Tylenol and the conditions.
